English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    L. А. Rieznik, Т. G. Starchenko, S. N. Koval, V. L. Shkapo

    THE ROLE OF GROWTH FACTORS IN THE DEVELOPMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS


    About the author: L. А. Rieznik, Т. G. Starchenko, S. N. Koval, V. L. Shkapo
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation The role of insulin-like growth factor-1 and transforming growth factor-β1 in the pathogenetic mechanisms of the formation of diastolic dysfunction of the left ventricle of the heart in patients with arterial hypertension and with type 2 diabetes mellitus were studied. 67 patients with type 2 diabetes mellitus and 46 with arterial hypertension and without diabetes mellitus patients were examined. Patients with arterial hypertension with concomitant diabetes mellitus were more marked than the diastolic function of the left ventricle. The relationship between the level of the transforming growth factor-β1 and the diastolic function of the left ventricle is established. In the presence of signs of diastolic dysfunction, the level of this growth factor was significantly higher in both groups of patients. The relationship between the level of insulin-like growth factor-1 and the indicators of diastolic function of the heart has not been established.
    Tags arterial hypertension,diabetes mellitus type 2,diastolic function of the left ventricle,insulin-like growth factor-1,transforming growth factor-β1
    Bibliography
    • Koval SM, Rieznik LA, Starchenko TH, Penkova MYu. Insulinopodibnyi faktor rostu-1 ta remodeliuvannia livoho shlunochka sertsia u khvorykh na arterialnu hipertenziiu z abdominalnym ozhyrinniam. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2021; 6(5): 178–183. doi: 10.26693/jmbs06.05.178. [in Ukrainian]
    • Koval SM, Starchenko TH, Rieznik LA, Penkova MYu. Transformuiuchyi faktor rostu-β1 v formuvanni patolohichnoho remodeliuvannia sertsia pry arterialnii hipertenzii z tsukrovym diabetom 2 typu ta ozhyrinniam. Ukrainskyi zhurnal medycyny, biolohii ta sportu. 2022; 7(5): 29–30. doi: 10.26693/jmbs07.05.102. [in Ukrainian]
    • Doetschan T, Barnett J, Runyan B. Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res. 2012; 347(1): 203. doi: 10.1007/s00441-011-1241-3
    • Groban L, Lin M, Kassik KA, Ingram RL, Sonntag WE. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Horm IGF Res. 2011; 21(2): 81–88. doi: 10.1016/j.ghir.2011.01.003.
    • Heger J, Schulz R, Euler G. Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure. British Journal of Pharmacology. 2016; 173 (1): 3–14. doi: 10.1111/bph.13344.
    • Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: an update on a topic at heart. Endocrine. 2015; 48(1): 25–35. doi: 10.1007/s12020-014-0327-6.
    • Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, et al.  Insulin-like growth factor – 1 induces Mdm2 and down-regulates p53, attenuating the myocyte rennin-angiotensin system and stretch-mediated apoptosis. Amer. J. Pathology. 1999; 154 (2): 567–580.
    • Ock S, Ham W, Kang CW, Kang H, Lee WS, Kim J. IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting αSMA. Cell Death Dis. 2021; 12(7): 688. doi: 10.1038/s41419-021-03965-5.
    • Ock S, Lee W S, Ahn J, Kim HM, Kang H, Kim H-S, et al.  Deletion of IGF-1 Receptors in Cardiomyocytes Attenuates Cardiac Aging in Male Mice. Endocrinology. 2016; 157(1): 336–345 doi: 10.1210/en.2015-1709.
    • Rubis P, Wisniovska-Smialek S, Wypasek E, Rudnicka-Sosin L, Hlawaty M, Leśniak-Sobelga A, et al. 12-month patterns of serum markers of collagen synthesis, transforming growth factor beta and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. Cytokine. 2017; 96: 217–227. doi: 10.1016/j.cyto.2017.04.021.
    • Walker A, Patel P A, Rajwani A, Groves D, Denby C, Kearney L, et al. Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction. Diabetes & Vascular Disease Research. 2016; 13(5): 331–340. doi: 10.1177/1479164116653342.
    • Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu C, et al. Mechanisms contributing to cardiac remodelling. Clin Sci (Lond). 2017; 131(18): 2319–2345. doi: 10.1042/CS20171167.
    • Yap J, Tay WT, Teng TK, Anand I, Richards AM, Ling LH, et al. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. Journal of the American Heart Association 2019; 8(17): e013114. doi: 10.1161/JAHA.119.013114.
    • Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract. 2017; 133: 124–130. doi: 10.1016/j.diabres.2017.08.018.
    • Yun SM, Kim SH, Kim EH. The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review. Front. Pharmacol. 2019; 10: 162. doi: 10.3389/fphar.2019.00162.
    Publication of the article «World of Medicine and Biology» №1(83), 2023 year, 152-155 pages, index UDK 616.12-008.331.1-092:616.379-008.64:577.175.8
    DOI 10.26724/2079-8334-2023-1-83-152-155